This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving treatment with Xeloda according to product label will be followed for up to 10 months.
Study Type
OBSERVATIONAL
Enrollment
563
Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
Unnamed facility
Vienna, Austria
Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment
Choice of line of treatment in adjuvant and advanced or metastatic cancer for capecitabine was observed.
Time frame: Approximately 3 years; or up to disease progression, death or stop of capecitabine treatment, whichever occurred first
Median Dose of Capecitabine
Median dose of capecitabine for treatment of metastatic colorectal cancer, adjuvant colon cancer, advanced gastric cancer, or metastatic breast cancer in this study was presented.
Time frame: Approximately 3 years; or up to disease progression, death or stop of capecitabine treatment, whichever occurred first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.